A recent study published in the Journal of Nuclear Medicine indicates that PSMA PET/CT imaging outperforms multiparametric MRI (mpMRI) in detecting bilateral intraprostatic disease and local staging in patients with intermediate or high-risk prostate cancer. The research found that PSMA PET/CT provided 18% higher accuracy than mpMRI and demonstrated significant sensitivity improvements compared to GRPR PET/CT and mpMRI. The combination of PSMA PET/CT with mpMRI further enhanced staging accuracy by 20% and improved detection of bilateral intraprostatic disease. Additionally, the study suggests that combined PSMA PET/CT and mpMRI staging is independently linked to worse biochemical recurrence-free survival (bRFS), highlighting its prognostic value over traditional factors like biopsy grade and PSA levels. While acknowledging certain limitations, including a small patient cohort, the findings advocate for the integration of PET/CT and MRI in clinical decisions regarding prostate cancer treatment strategies.
Mon, 09 Feb 2026 13:10:36 GMT | diagnosticimaging.com